Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 17/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101042 | 0.92 | PTGES (0.45) | PTGESLRRK2 | |
| SCHEMBL3101035 | 0.92 | PTGES (0.45) | PTGESLRRK2 | |
| SCHEMBL3226029 | 0.85 | PTGES (0.46) | PTGESLRRK2 | |
| SCHEMBL3226021 | 0.85 | PTGES (0.46) | PTGESLRRK2 | |
| SCHEMBL3106287 | 0.84 | PTGES (0.47) | PTGES | |
| SCHEMBL10091497 | 0.83 | PTGES (0.43) | PTGESPDE5A | |
| SCHEMBL10091458 | 0.83 | PTGES (0.45) | PTGES | |
| SCHEMBL10091495 | 0.82 | PTGES (0.54) | PTGES | |
| SCHEMBL16509616 | 0.82 | PTGES (0.61) | PTGESLRRK2 | |
| SCHEMBL1973380 | 0.82 | PTGES (0.61) | PTGESLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218670-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | GESYNTA PHARMA AB (SE) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218670-A1 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION | PTGIS, PTGIR, PTGER1 | PTGES 4/4885LRRK2 4398/4885PDE5A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.